NovaBay Pharmaceuticals Fulfills $1 Million Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings
May 01 2023 - 6:50AM
Business Wire
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces
that China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a
leading Chinese importer and marketer of branded pharmaceuticals
and medical devices, has placed a $1 million order for NovaBay’s
NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this
order and expects to recognize this revenue in the second quarter
of 2023.
“NeutroPhase is the safest, purest and most powerful
hypochlorous acid wound cleanser on the market yet is gentle,
non-irritating and non-sensitizing to skin and new tissue,” said
Justin Hall, CEO of NovaBay Pharmaceuticals. “Importantly,
NeutroPhase differentiates itself in the marketplace because it
does not contain the toxic chemicals found in many other wound care
products. We proudly manufacture NeutroPhase in the U.S. in large
batch quantities through a proprietary process.”
“The efficacy of NeutroPhase is unparalleled in the wound care
market. We are proud of our long-term partnership with NovaBay and
are delighted to make this high-quality product available to our
healthcare customers in China,” said Paul Li, Chairman of China
Pioneer.
About NeutroPhase
Laboratory tests show that NeutroPhase kills the bacteria that
infect wounds to neutralize the toxins that impede healing and
destroy healthy tissue. NeutroPhase can be used on any wound and as
frequently as needed, without any toxicity concerns. Hypochlorous
acid is part of the body’s natural immune system that combats acute
infections and promotes the healing of chronic wounds. Among the
benefits of hypochlorous acid is its ability to penetrate and kill
biofilm, which represents a significant barrier to wound
healing.
In the U.S. NovaBay manufactures its proprietary wound care
product under the PhaseOne® brand, which is distributed for
professional use by PhaseOne Health. The effectiveness of PhaseOne
is independently documented in the study “Comparative Antimicrobial
Activity of Commercial Wound Care Solutions on Bacterial and Fungal
Biofilms” (Harriott, PhD et al) published in the peer-reviewed
journal Annals of Plastic Surgery.
About China Pioneer Pharma Holdings, Limited
Founded in 1996, China Pioneer Pharma Holdings, Limited is one
of the largest comprehensive marketing, promotion and channel
management service providers dedicated to importing pharmaceuticals
and medical devices into China. China Pioneer regularly introduces
advanced-technology products to benefit patients across China. More
information is available at www.pioneer-pharma.com.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
consumers through online distribution channels such as Amazon.
DERMAdoctor® offers more than 30 OTC dermatologist-developed
skincare products through the DERMAdoctor website, well-known
traditional and digital beauty retailers, and international
distributors. NovaBay also manufactures and sells effective, yet
gentle and non-irritating wound care products. The PhaseOne® brand
is distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by China Pioneer Pharma Holdings, Limited.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005052/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024